Publication | Open Access

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease

Hematological MalignancyResidual DiseaseImatinib Versus ImatinibMedicineChronic Myeloid LeukaemiaMixed-phenotype Acute LeukemiaHematologyPathologyOncologyCancer ResearchMyeloid Neoplasia